---
title: "BioNTech’s rally on Moderna trial win likely to fade, Leerink says"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296380155.md"
description: "Leerink Partners analyst Daina Graybosch predicts BioNTech's recent 21% rally will fade, despite Moderna and Merck's Phase 3 trial success for a melanoma therapy. She argues investors will absorb poor read-through for BioNTech, whose iNEST program has been negatively impacted by prior negative data."
datetime: "2026-08-19T16:16:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296380155.md)
  - [en](https://longbridge.com/en/news/296380155.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296380155.md)
generator: "portal-rs"
---

# BioNTech’s rally on Moderna trial win likely to fade, Leerink says


### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Wolfe Research Just Upgraded Moderna Stock. Here's Why.](https://longbridge.com/en/news/296951590.md)
- [Moderna Stock (MRNA) Slides 3% on Plans for a $2B Private Placement](https://longbridge.com/en/news/297195128.md)
- [Cancer vaccine win restores Wall Street’s faith in Moderna](https://longbridge.com/en/news/296811597.md)
- [Moderna plans private placement of $2 billion convertible senior notes offering](https://longbridge.com/en/news/297176043.md)
- [Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes  | MRNA Stock News](https://longbridge.com/en/news/297314560.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**